Literature DB >> 9520967

On estimating costs for economic evaluation in failure time studies.

A P Hallstrom1, S D Sullivan.   

Abstract

Only recently have attempts been made to adjust for the bias censoring can impart on economic estimates based on data obtained during a clinical trial. This article reviews a suggested approach that adopts techniques developed for adjusting for the effect of censoring on estimation of failure time. The authors show that this approach does not provide unbiased estimation and explain the reason why this is the case.

Mesh:

Year:  1998        PMID: 9520967     DOI: 10.1097/00005650-199803000-00019

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  5 in total

1.  Some insight on censored cost estimators.

Authors:  H Zhao; Y Cheng; H Bang
Journal:  Stat Med       Date:  2011-07-11       Impact factor: 2.373

2.  Estimating mean total costs in the presence of censoring: a comparative assessment of methods.

Authors:  Tracey A Young
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout Session.

Authors:  Henry J Henk; Ya-Chen Tina Shih; Bijan J Borah
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

4.  Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

Authors:  Helen A Dakin; Sarah Wordsworth; Chris A Rogers; Giselle Abangma; James Raftery; Simon P Harding; Andrew J Lotery; Susan M Downes; Usha Chakravarthy; Barnaby C Reeves
Journal:  BMJ Open       Date:  2014-07-29       Impact factor: 2.692

5.  Long-term costs of colorectal cancer treatment in Spain.

Authors:  Julieta Corral; Xavier Castells; Eduard Molins; Pietro Chiarello; Josep Maria Borras; Francesc Cots
Journal:  BMC Health Serv Res       Date:  2016-02-16       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.